-
.
- Acer Rehabs Inc ACER introduced topline outcomes from its Stage 2a evidence of idea medical test to assess ACER-801 (osanetant) as a possible therapy for modest to serious Vasomotor Signs (VMS) related to menopause.
- .
- Acer Therapy Broadens ACER-801 Growth Into Trauma .
- .
- .
- Sanofi SA SNY to get globally civil liberties to ACER-801 (osanetant). .
- ACER shares are down 39.96% at $0.9306 on the last check Friday. .
.(* )The research revealed that ACER-801 was risk-free as well as well-tolerated however did not attain analytical value when examining ACER-801’s capability to lower the regularity or seriousness of warm flashes in postmenopausal females.
Connected:
Thus, Acer is stopping briefly the ACER-801 program till Acer has actually completely evaluated the complete information collection.
Acer is remaining to concentrate on prep work for its industrial launch of OLPRUVA (salt phenylbutyrate) for urea cycle problems as well as the recurring Stage 3 test of EDSIVO (celiprolol) for vascular Ehlers-Danlos Disorder in individuals with a verified kind III collagen anomaly, based on schedule of added funding past very early in Q2 2023.
In December 2018, Acer became part of an unique certificate arrangement with
Rate Activity:
© 2023 Benzinga.com. Benzinga does not give financial investment suggestions. All civil liberties scheduled.
